DEFA14A: Akero Therapeutics Updates Merger Proxy, Addresses Lawsuits

Akero Therapeutics filed a supplement to its definitive proxy statement for the upcoming special meeting, providing additional disclosures regarding its proposed merger with Novo Nordisk and addressing two stockholder lawsuits.

Summary

• Akero Therapeutics filed definitive additional materials on November 24, 2025, to amend and supplement its definitive proxy statement dated November 7, 2025, for a special meeting of stockholders.
• The Special Meeting, scheduled for December 2, 2025, is to consider and vote upon the Agreement and Plan of Merger with Novo Nordisk A/S and NN Invest Sub, Inc., including a contingent value rights (CVR) agreement.
• Merger Sub will merge with and into Akero, with Akero surviving as a wholly owned subsidiary of Novo Nordisk.
• As of November 24, 2025, two lawsuits (John Burke vs. Akero Therapeutics, Inc., et al., and Andrew Thompson vs. Akero Therapeutics, Inc., et al.) have been filed in the Supreme Court of the State of New York.
• These complaints allege that the proxy statement omits material information and contains misleading disclosures, seeking injunctive relief to prevent merger consummation, rescission or damages if consummated, and plaintiffs' fees.
• Akero, Novo Nordisk, and Merger Sub believe these claims and similar demand letters are without merit.
• Supplemental disclosures include details on the engagement of financial advisors Morgan Stanley and J.P. Morgan, the formation and authority of the Transaction Committee, and updated financial projections.
• Morgan Stanley and J.P. Morgan performed discounted cash flow analyses and reviewed analyst price targets and precedent transactions for reference in their fairness opinions.
• The October Projections (risk-adjusted) forecast efruxifermin revenues for MASH patients with stage 3 or 4 fibrosis, assuming a 57.4% cumulative probability of success, and do not include revenue from stage 2 fibrosis or other pipeline products.
• The October Projections reflect an increase of approximately $436 million in assumed operating expenses over the 2026-2028 period, primarily for Phase 3 clinical trials, manufacturing, and commercialization preparation, compared to May Projections.

Sentiment

Score: 5

Explanation: The filing provides necessary supplemental information for a pending merger vote and addresses ongoing legal challenges. While the merger itself is a significant event, the supplement highlights litigation risks and increased operating expenses in projections, balancing the overall sentiment to neutral.

Positives

• The company is progressing with a proposed merger with Novo Nordisk, offering a potential strategic exit for shareholders.
• The Board of Directors formed a Transaction Committee, composed of independent and disinterested members, to oversee and direct management and advisors regarding strategic alternatives, indicating a structured review process.
• Financial advisors Morgan Stanley and J.P. Morgan provided fairness opinions to the Board of Directors, supporting the financial terms of the proposed merger.
• Akero, Novo Nordisk, and Merger Sub believe the claims asserted in the stockholder lawsuits are without merit, suggesting confidence in their disclosures and the merger process.

Negatives

• Two lawsuits have been filed by purported stockholders alleging material omissions and misleading disclosures in the proxy statement, which could lead to delays or complications for the merger.
• The lawsuits seek injunctive relief to prevent the consummation of the merger, which poses a direct threat to the transaction's timeline and certainty.
• The October Projections reflect an increase of approximately $436 million in assumed operating expenses over the 2026-2028 period compared to earlier May Projections, indicating higher anticipated costs for clinical trials and commercialization.
• Financial advisors used a perpetual growth rate of negative 50% for terminal value calculations in their discounted cash flow analyses, which is a highly conservative assumption.

Risks

• Uncertainties exist regarding the ability to obtain shareholder approval for the Transactions.
• The occurrence of any event, change, or circumstance could lead to the termination of the Merger Agreement, potentially requiring a party to pay a termination fee.
• There is a risk that the parties may not be able to consummate the Transactions on a timely basis or at all.
• Holders of Contingent Value Rights (CVRs) face the risk of not receiving any payments if CVR milestones are not achieved.
• The possibility of competing offers for Akero could emerge.
• Various closing conditions, including securing regulatory and stockholder approvals, may not be satisfied or waived, or a governmental entity may prohibit, delay, or refuse approval for the Transactions.
• The Transactions (or their announcement/pendency) could negatively impact relationships with associates, customers, manufacturers, suppliers, employees, other business partners, or governmental entities.
• Predicting the timing or outcome of FDA approvals or actions is difficult and uncertain.
• The impact of competitive products and pricing could adversely affect Akero's business.
• Novo Nordisk (Parent) may not realize the potential benefits of the Transactions.
• Transaction costs could be significant.
• The Transactions may divert management's attention from Akero's ongoing business operations or otherwise disrupt them.
• Changes in Akero's business during the period between now and the closing of the Transactions could occur.
• Certain restrictions during the pendency of the Transactions may limit Akero's ability to pursue business opportunities or strategic transactions.
• Risks are associated with litigation relating to the Transactions, including potential delays or adverse effects on consummation.
• The ability to maintain or expand regulatory approvals or commercialize Akero's products is uncertain.
• Results of any ongoing or future clinical trials may not satisfy U.S. or non-U.S. regulatory authorities.
• Uncertainty from current worldwide economic and financial conditions, including pandemics, inflation, interest rates, natural disasters, military conflicts, and terrorist attacks, could impact the company.
• Actual or contingent liabilities could arise.

Future Outlook

The future outlook is primarily centered on the successful consummation of the proposed merger with Novo Nordisk. This includes the ability to obtain shareholder and regulatory approvals, and the potential for Akero to achieve contingent value right (CVR) milestones related to efruxifermin. The financial projections extend to 2041, forecasting significant revenue growth for efruxifermin for MASH patients with stage 3 or 4 fibrosis, assuming a 57.4% probability of success. The company also anticipates the potential for FDA approval of efruxifermin and the commercialization of current and future product candidates.

Management Comments

• Akero, Parent and Merger Sub believe the claims asserted in these complaints are without merit.
• Akero, Parent and Merger Sub believe the claims asserted in these demand letters are also without merit.
• Akero believes that no further disclosure is required to supplement the Definitive Proxy Statement under applicable law; however, to avoid the risks and uncertainties inherent in litigation and the risk that lawsuits may delay or otherwise adversely affect the consummation of the proposed Merger and to minimize the expense of defending such actions, Akero wishes to voluntarily make supplemental disclosures related to the proposed Merger, which are set forth below, in response to certain allegations.

Industry Context

The proposed acquisition of Akero Therapeutics by Novo Nordisk is indicative of the ongoing strategic consolidation within the biopharmaceutical industry, particularly in therapeutic areas with high unmet needs like metabolic dysfunction-associated steatohepatitis (MASH). The detailed financial analyses by two prominent investment banks (Morgan Stanley and J.P. Morgan) and the inclusion of a Contingent Value Rights (CVR) agreement are common features in complex biopharma M&A transactions, reflecting efforts to value pipeline assets and manage development risks. The litigation faced by Akero is also a recurring theme in large public company mergers, where shareholder lawsuits often challenge the adequacy of disclosures or the fairness of deal terms.

Comparison to Industry Standards

• Morgan Stanley and J.P. Morgan reviewed 77 M&A transactions announced between May 2016 and September 2025 involving late-stage or marketed publicly traded biopharma companies with upfront consideration valued between $1 billion and $15 billion.
• The median percentage premia paid over the unaffected stock price in these selected transactions was 73%.
• Based on their analysis, the financial advisors selected a range of premia to unaffected stock price of 37% to 117% (representing the 10th and 90th percentiles) for comparison.

Corporate Governance

Legal Proceedings

• John Burke vs. Akero Therapeutics, Inc., et al., Index No. 659669/2025, filed November 10, 2025, in the Supreme Court of the State of New York, County of New York.
• Andrew Thompson vs. Akero Therapeutics, Inc., et al., Index No. 659714/2025, filed November 11, 2025, in the Supreme Court of the State of New York, County of New York.
• Both complaints allege that the proxy statement issued in connection with the Merger omits material information and contains misleading disclosures, violating New York common law.
• The lawsuits seek injunctive relief preventing consummation of the merger, rescission of the transactions or an award of actual and punitive damages if consummated, and an award of plaintiffs' fees and expenses.
• Akero has also received certain demand letters from purported stockholders making similar allegations.
• Akero, Novo Nordisk, and Merger Sub believe the claims asserted in these complaints and demand letters are without merit.

Stakeholder Impact

• Shareholders: Will vote on the proposed merger and are directly impacted by the merger consideration, including potential CVR payments. The ongoing litigation introduces uncertainty regarding the merger's consummation and potential value.
• Employees: The merger (or its announcement/pendency) could affect relationships with employees, including risks related to retaining or hiring key personnel.
• Customers, Manufacturers, Suppliers, Other Business Partners: Relationships with these parties may be impacted by the effects of the Transactions or their announcement/pendency.
• Creditors: The company's financial condition and future operations post-merger could indirectly affect creditors, though no specific impact is detailed in this supplement.

Next Steps

• Stockholders are urged to submit their proxies promptly for the Special Meeting.
• The Special Meeting of Stockholders will be held on December 2, 2025, to vote on the Merger Agreement.
• Consummation of the proposed Merger, subject to shareholder approval and satisfaction of closing conditions.
• Akero is required to use reasonable best efforts to execute the Development Plan under the Merger Agreement with Novo Nordisk.
• Potential future FDA approval of Akero's new drug application for efruxifermin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
• Potential commercialization of current and future product candidates.

Key Dates

Recommendation

The filing is a supplement to a proxy statement for a pending merger, primarily addressing legal challenges and providing additional disclosures. While the merger with Novo Nordisk offers a clear path for shareholder value realization, the ongoing lawsuits seeking injunctive relief introduce significant uncertainty regarding the deal's timely completion and potential terms. The detailed financial projections, while informative, are based on management assumptions and include increased operating expenses. Given the procedural nature of this filing and the unresolved litigation, a 'hold' recommendation is appropriate as investors await the outcome of the shareholder vote and the resolution of legal risks before making further investment decisions.

Keywords

Akero Therapeutics, Novo Nordisk, Merger, Acquisition, Proxy Statement, SEC Filing, DEFA14A, Biopharma M&A, Shareholder Vote, Litigation, Financial Advisors, Fairness Opinion, Discounted Cash Flow, Contingent Value Rights, CVR, MASH, Efruxifermin, Clinical Trials, Corporate Governance